ZBH Stock Price Zimmer Biomet Holdings Inc Stock Quote U.S.: NYSE

Approximately 70% of its revenue comes from sales of large joints, while the remaining quarter is derived from extremities, trauma, and related surgical products. Over the past few years, Zimmer Biomet has reported Que es swing trading steady financial performance. The company has reported increased revenue and profit margin for the past several years while also reporting a debt-to-equity ratio indicating a relatively low debt level.

• U.S. sales rose 5% in the second quarter, well ahead of the company’s expectations, with elective procedure volumes recovering and procedure cancellation rates returning to pre-pandemic levels.
• The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015.
• The company’s hip and knee replacement products continue to enjoy solid demand.
• The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
• The industry is also highly regulated, with various regulatory bodies overseeing the safety and efficacy of medical devices.

Additionally, Zimmer Biomet’s executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. Some of the biggest medical device companies’ stocks have dropped to attractive prices due to the current COVID-19 pandemic. First quarter net sales of $1.831 billion increased 10.1% and 13.2% on a constant currency1 basis First quarter diluted earnings per share were $1.11; adjusted1 diluted earnings per share were $1.89 C… Second quarter net sales of $1.870 billion increased 4.9% and 6.0% on a constant currency1 basis Second quarter diluted earnings per share were $1.00; adjusted1 diluted earnings per share were $1.82 C… Zimmer Biomet (ZBH Quick QuoteZBH – Free Report) is well-poised for growth in the coming quarters, backed by a strong recovery in its business. Zimmer Biomet’s Knee business to drive pricing stability, mix benefit and competitive conversions.

Financial Strength

In addition, insurance and hospital reimbursement policy changes could also impact the demand for Zimmer Biomet’s products. U.S. sales rose 5% in the second quarter, well ahead of the company’s expectations, with elective procedure volumes recovering and procedure cancellation rates returning to pre-pandemic levels. International sales grew 7.2%, driven by strong EMEA and Asia Pacific performance.

• The company’s leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017.
• There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock.
• Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets.
• The company issued revenue guidance of $7.39 billion-$7.43 billion, compared to the consensus revenue estimate of $7.40 billion.

Integer Holdings, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%. HealthEquity, carrying a Zacks Rank #2 (Buy) at forex trading fundamentals present, has an estimated long-term growth rate of 23.5%. HQY’s earnings surpassed estimates in all the trailing four quarters, with an average of 13%. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries.

The company’s hip and knee replacement products continue to enjoy solid demand. In the past year, this Zacks Rank #3 (Hold) stock has increased 7.6% compared with the 1.2% rise of the industry and the 20.3% rise of the S&P 500 composite. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. To find high-quality companies that may deliver above-average returns, please check out the GuruFocus High Quality Low Capex Screener. Stockholders of record on Friday, September 29th will be paid a dividend of $0.24 per share on Tuesday, October 31st.

Poaches Zimmer Biomet CEO Hanson to Lead Healthcare Spinoff >MMM ZBH

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015.

Zimmer Biomet Holdings Inc. stock rises Thursday, outperforms market

A faster-growing company creates more value for shareholders, especially if the growth is profitable. However, the 3-year average annual revenue growth of Zimmer Biomet Holdings is -5.1%, ranking worse than 78.11% of 731 companies in the Medical Devices & Instruments industry. Its 3-year average EBITDA growth rate is -11.8%, ranking worse than 78.46% of 738 companies in the same industry. Zimmer Biomet Holdings is a leading player in the design, manufacture, and marketing of orthopedic reconstructive implants, alongside supplies and surgical equipment for orthopedic surgery. With its acquisitions of Centerpulse in 2003 and Biomet in 2015, the company holds a commanding share of the reconstructive market in the United States, Europe, and Japan.

Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products trading fractals offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. GuruFocus research has found that growth is closely correlated with the long-term stock performance of a company.

The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. You can find your newly purchased ZBH stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Final Trades: Zimmer, Inmode & more

An indication of interest to purchase securities involves no obligation or commitment of any kind. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. The orthopedic industry is highly competitive, with a few major players dominating the market. Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets. The industry is also highly regulated, with various regulatory bodies overseeing the safety and efficacy of medical devices. Zimmer Biomet has a track record of complying with regulatory requirements and maintaining high-quality standards.

Another risk facing Zimmer Biomet is the potential for increased competition. While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants. To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development.

This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. Use these ten stocks to generate a safe and reliable source of investment income. Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per share from continuing operations was $0.62; …